1. Australia Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Anagenics Limited

Anagenics Limited

AASX:AN1
0.01
AUD
0.00
(0.00%)
0.00EPS
2.48MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.02
0.06
0.04
0.06
0.08
0.09
0.09
0.07
0.04
0.04
0.03
0.03
0.01
Basic EPS, GAAP
-0.05
-0.04
-0.08
-0.07
-0.08
-0.06
-0.07
-0.05
-0.02
-0.02
-0.01
-0.02
- -
Free Cash Flow per Basic Share
-0.05
-0.06
-0.08
-0.05
-0.07
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
0.14
0.09
0.09
0.08
0.03
0.06
0.07
0.06
0.04
0.02
0.01
- -
Tangible Book Value per Share
0.09
0.09
0.04
0.05
0.04
- -
0.04
0.06
0.05
0.02
0.01
- -
- -
Basic Weighted Avg Shares
31
38
42
49
55
60
82
106
143
211
266
399
469
Sales/Revenue/Turnover
1
2
2
3
4
6
7
7
6
9
9
11
5
Operating Margin (%)
-472.02
-127.28
-239.99
-153.27
-114.44
-78.68
-96.29
-87.14
-77.78
-49.4
-25.63
-68.28
-27.8
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
1
- -
Net Income, GAAP
-2
-1
-3
-3
-4
-4
-6
-5
-3
-4
-3
-8
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-281.9
-67.09
-181.1
-112.13
-99.42
-66.09
-80.93
-66.49
-58.23
-39.51
-29.27
-71.68
-26.04
Working Capital
3
4
2
3
3
2
4
8
9
5
5
2
- -
LT Debt
- -
- -
- -
- -
- -
1
1
1
1
1
- -
- -
- -
Total Equity
5
6
4
5
4
2
6
10
10
8
9
3
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-40.96
-26.8
-70.72
-82.68
-98.41
-119.09
-152.89
-62.64
-33.46
-38.97
-31.04
-133.46
-54.48

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.18%
-21.8%
-32.6%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
11.36%
11.23%
-84.04%
Sales/Revenue/Turnover
16.81%
-0.26%
-56.07%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
9
2024
- -
- -
11
2025
- -
- -
5

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.02
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chris Lewis
Full Time Employees
11
Sector
Consumer non-durables
Industry
Household/Personal care
Address
55 Clarence Street Sydney NSW Australia 2000
IPO Date
Jun 11, 2005
Website
anagenics.com
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Anagenics Limited (ASX:AN1) operates as an Australia-based health and beauty-tech company focused on the beauty, health, and wellness sector, developing, manufacturing, and marketing premium branded consumer products including anti-ageing hair care under the Evolis brand, skin, hair, and body care under the Uspa brand, and distributing leading skincare and beauty products through its subsidiary BLC Cosmetics to spas, clinics, salons, retail stores, and online channels; it serves wholesale and retail customers via omnichannel distribution primarily in Australia, New Zealand, the Pacific Islands, and Japan. Founded in 2004 and headquartered in Sydney, the company originally started as a biotechnology firm targeting inflammatory diseases and hair loss therapies before evolving into its current consumer-focused portfolio emphasizing clinically validated anti-aging solutions for hair, skin, and body to help consumers live longer in good health. Recent developments include a Midkine Antibody Licensing Deal in May 2024, a licensing partnership announced in July 2024 driving 16% FY2024 revenue growth, completion of the Face Medi Group sale in October 2024, ongoing corporate restructuring updates through December 2024 involving FOS Capital, director resignations, trading suspensions in September 2024, and a proposed securities issue in January 2025.